Core Viewpoint - Zhongheng Group's subsidiary, Laimei Pharmaceutical, is participating in the 11th batch of national centralized drug procurement and aims to be selected for the procurement of Nicorandil tablets, which have not yet commenced sales [1] Group 1 - The potential selection for procurement could enhance product sales and market expansion for the company [1] - Successful procurement and contract signing would positively impact the company's brand influence and long-term development [1] - There are uncertainties regarding the bidding results and contract signing, and various factors affect drug production and sales [1]

Core Viewpoint - The company, Lai Mei Pharmaceutical, has participated in the 11th national centralized drug procurement organized by the National Drug Procurement Office, with its product Nicorandil tablets proposed for selection in this procurement process [1] Group 1: Company Information - Lai Mei Pharmaceutical announced its participation in the national centralized drug procurement bidding on October 30 [1] - The product Nicorandil tablets (5mg) received its drug registration certificate from the National Medical Products Administration in September 2025, but has not yet commenced sales [1]

证券代码：300006 证券简称：莱美药业 公告编号：2025-054 重庆莱美药业股份有限公司 关于参加第十一批全国药品集中采购拟中选的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或 重大遗漏。 重庆莱美药业股份有限公司（以下简称"公司"）参加了由国家组织药品联合采购 办公室（简称"联采办"）组织开展的第十一批全国药品集中采购投标工作。根据联采 办发布的《全国药品集中采购拟中选结果公示》，公司产品尼可地尔片拟中选本次 集中采购，现将相关情况公告如下： 注：该产品的拟中选价格、拟中选数量及拟供应省区均以联采办发布的最终数据为准。 二、本次拟中选对公司的影响 2025 年 10 月 30 日 一、拟中选产品基本情况 拟中选 产品 规格包装 注册分类 适应症 拟中选价格 拟中选数量 拟供应省区 尼可地 尔片 5mg 化学药品 4 类 心绞痛 2.95 元/盒 以 联 采 办 发 布 的 最 终 数 据 为 准。 以联采办发 布的最终数 据为准。 公司上述拟中选产品尼可地尔片（规格：5mg）于 2025 年 9 月取得国家药品监 督管理局核准签发的《药品注册证书》，截至目前该 ...

Core Viewpoint - Recently, the company reported a decline in revenue and incurred losses for the first three quarters of 2025, indicating challenges in its financial performance [1] Financial Performance - For the first three quarters of 2025, the company achieved operating revenue of 581 million, a year-on-year decrease of 4.1% [1] - The net profit attributable to the parent company was a loss of 45.92 million [1] - In the third quarter, the operating revenue was 204 million, reflecting a year-on-year decline of 8.9% [1] - The net profit attributable to the parent company for the third quarter was a loss of 14.54 million [1] Regulatory Approvals - During the reporting period, the company received approval from the National Medical Products Administration for the injection of Mycophenolate Mofetil (specification: 0.5g) and obtained drug registration certificates for Nicorandil tablets (specification: 5mg) and Ketorolac Tromethamine injection (specification: 1ml: 30mg) [1] Shareholding Changes - On September 26, 2025, the company was notified by its controlling shareholder, Guangxi Wuzhou Zhongheng Group Co., Ltd. (hereinafter referred to as "Zhongheng Group"), about a capital increase agreement and share transfer agreement signed by its indirect controlling shareholder, Guangxi Investment Group Co., Ltd. (hereinafter referred to as "Guangxi Investment Group") [1] - Guangxi Investment Group plans to increase capital in Guangxi Investment Group Financial Holdings Co., Ltd. (hereinafter referred to as "Guangxi Financial Holdings") by transferring 859,343,587 shares of Zhongheng Group [1] - After the completion of this transaction, Guangxi Financial Holdings will become the indirect controlling shareholder of the company, while Zhongheng Group will remain the direct controlling shareholder, and the Guangxi State-owned Assets Supervision and Administration Commission will continue to be the actual controller of the company [1]

Core Viewpoint - Laimei Pharmaceutical reported a decline in revenue and net profit for the first three quarters of 2025, but is making progress in consolidating its core products, advancing R&D, and digital transformation [1][2] Financial Performance - The company achieved operating revenue of 581 million yuan, a year-on-year decrease of 4.06% [1] - The net profit attributable to shareholders was -45.92 million yuan, with a net profit of -48.38 million yuan after excluding non-recurring gains and losses [1] - Basic earnings per share were -0.04 yuan [1] Strategic Initiatives - Laimei Pharmaceutical is focusing on consolidating the market leadership of its flagship product, Canalin, while accelerating the introduction and market transition of new products [1] - The company is expanding its business through innovative generic product R&D and technology introduction [1] - Several products, including Voriconazole tablets and Paclitaxel injection, have been awarded bids in multiple provincial procurement projects, indicating the gradual emergence of scale effects [1] Digital Transformation - The company has initiated a digital construction project integrating business and finance, aiming to enhance operational precision and compliance management capabilities [1] Future Outlook - For the fourth quarter, Laimei Pharmaceutical plans to accelerate new drug R&D, consistency evaluation, and high-quality innovative generic product research [2] - The company aims to optimize its product structure based on targeted tumor innovative drugs and cell immunotherapy R&D platforms, seeking to introduce new profit growth points and enhance core competitiveness [2] - Industry insiders suggest that the company needs to strengthen R&D conversion efficiency and cost control to gradually improve performance amid the pharmaceutical industry's transformation [2]

Core Insights - The company reported a revenue of 581 million yuan for the first three quarters of 2025, representing a year-on-year decline of 4.06% [1] - The net profit attributable to shareholders for the same period was -45.92 million yuan [1] - In the third quarter, the company achieved a revenue of 204 million yuan, which is a year-on-year decrease of 8.95% [1] - The net profit attributable to shareholders in the third quarter was -14.54 million yuan [1]

Core Insights - Laimei Pharmaceutical reported a revenue of 581 million yuan and a net loss of 45.91 million yuan for the first three quarters, with a third-quarter revenue of 204 million yuan and a net loss of 14.54 million yuan, indicating a reduction in losses year-on-year [2] Product Developments - The company achieved significant progress with multiple products, enhancing its product pipeline and market competitiveness [2] - Laimei received approval from the National Medical Products Administration for the injection of Mycophenolate Mofetil (0.5g) and registered two other drugs: Nicorandil tablets (5mg) and Ketorolac Tromethamine injection (1ml: 30mg) [2][3] Market Performance - Mycophenolate Mofetil is an immunosuppressant used to prevent acute organ rejection in kidney and liver transplant patients, with sales in China's hospital market projected to grow from 32.89 million yuan in 2022 to 60.59 million yuan in 2024 [2] - Nicorandil tablets, used for treating angina, are expected to see sales increase from 676 million yuan in 2022 to 873 million yuan in 2024 [3] - Ketorolac Tromethamine injection, indicated for moderate to severe postoperative pain, is projected to have sales of 2.643 billion yuan in 2022, decreasing to 898 million yuan by 2024 [3] Future Strategy - The company plans to focus on its strengths in niche markets, continue introducing new products, accelerate the market launch of newly introduced products, and enhance its innovation efforts to navigate opportunities and challenges in the pharmaceutical industry [3]

格隆汇10月21日丨莱美药业(300006.SZ)公布2025年第三季度报告，营业收入为2.04亿元，同比下降 8.95%；归属于上市公司股东的净利润为-1453.99万元；归属于上市公司股东的扣除非经常性损益的净 利润为-1614.58万元。 ...

Core Viewpoint - Laimei Pharmaceutical (300006.SZ) reported a decline in revenue and an increase in net loss for the first three quarters of 2025 compared to the previous year [1] Financial Performance - The company's operating revenue for the first three quarters was 581 million yuan, representing a year-on-year decrease of 4.06% [1] - The net loss attributable to shareholders of the listed company was 45.9172 million yuan [1] - The net loss attributable to shareholders, excluding non-recurring gains and losses, was 48.379 million yuan [1] - The basic loss per share was 0.0435 yuan [1]

证券代码：300006 证券简称：莱美药业 公告编号：2025-052 具体内容详见公司同日在巨潮资讯网（http://www.cninfo.com.cn）披露的 《重庆莱美药业股份有限公司 2025 年第三季度报告》。 表决结果：9 票同意、0 票反对、0 票弃权。 二、备查文件 1、重庆莱美药业股份有限公司第五届董事会第四十八次会议决议； 重庆莱美药业股份有限公司 第五届董事会第四十八次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 重庆莱美药业股份有限公司（以下简称"公司"）董事会办公室于 2025 年 10 月 15 日以通讯方式向全体董事送达召开第五届董事会第四十八次会议的 通知。本次会议于 2025 年 10 月 20 日（星期一）以通讯表决方式召开。本次 会议应出席董事 9 名，实际出席董事 9 名。本次会议的召集、召开符合《中 华人民共和国公司法》《公司章程》及有关法律法规的规定。本次会议由公 司董事长梁建生先生主持。经公司出席会议董事审议和逐项书面表决，形成 了以下决议： 一、审议通过了《关于<2025 年第三季度报告>的议案》 ...